Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YK0901
- Development stage
- Phase 1
- Lead developer
- Yingkai Saiwei
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
YK0901 is a KRAS G12V-specific T cell receptor (TCR) modified T cell therapy. It functions as a KRAS G12V inhibitor through immunologic cytotoxicity and T lymphocyte replacement mechanisms. This therapy is designed for patients with advanced solid tumors who are HLA-A*11:01 positive and have KRAS G12V mutations, which are common in pancreatic, lung, and colorectal cancers.
02
Targets
KRAS G12V/HLA-A*11:01 (KRAS G12V Mutant Peptide-HLA-A*11:01 Complex)KRASG12V (KRAS G12V)
Beyond the preview
Go deeper on YK0901.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YK0901.